Glenmark Pharmaceuticals · NSE: GLENMARK · BSE: 532296
Q1 FY27 results · Apr–Jun 2026
Glenmark Pharmaceuticals reported revenue from operations of ₹4,018.48 crore (up 23.1% from Q1 FY26) and net profit of ₹482.83 crore (up 927.9% from Q1 FY26) for Q1 FY27 (Apr–Jun 2026), on a consolidated basis.
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 4,018.48 | 3,264.44 | +23.1% | 3,770.59 | +6.6% |
| Other income | 65.76 | 26.44 | +148.7% | 189.08 | −65.2% |
| Total income | 4,084.25 | 3,290.88 | +24.1% | 3,959.67 | +3.1% |
| Profit before tax | 643.39 | 95.58 | +573.2% | 387.77 | +65.9% |
| Net profit for the period | 482.83 | 46.97 | +927.9% | 301.32 | +60.2% |
| Attributable to shareholders of the company | 482.92 | 46.87 | +930.3% | (0.10) | Turned profit |
| EPS, basic (₹) | 17.11 | 1.66 | +930.7% | 10.68 | +60.2% |
| Net margin (%) | 12.0 | 1.4 | 8.0 |
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,434.99 | 2,394.93 | +1.7% | 2,146.58 | +13.4% |
| Other income | 115.41 | 69.33 | +66.5% | 307.88 | −62.5% |
| Total income | 2,550.40 | 2,464.26 | +3.5% | 2,454.45 | +3.9% |
| Profit before tax | 866.10 | 401.17 | +115.9% | (107.40) | Turned profit |
| Net profit for the period | 735.64 | 330.23 | +122.8% | (73.90) | Turned profit |
| EPS, basic (₹) | 26.07 | 11.70 | +122.8% | (2.62) | Turned profit |
| Net margin (%) | 30.2 | 13.8 | -3.4 |
Consolidated
- Filed with BSE
- 31 Jul 2026, 19:51 IST
- Board meeting
- 31 Jul 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 31 Jul 2026, 19:51 IST
- Board meeting
- 31 Jul 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE